HC Wainwright Cuts Earnings Estimates for Rockwell Medical

Rockwell Medical, Inc. (NASDAQ:RMTI) – Stock analysts at HC Wainwright dropped their Q1 2027 earnings estimates for shares of Rockwell Medical in a research note issued on Friday, September 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.02 per share for the quarter, down from their prior forecast of $0.05. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2027 earnings at $0.14 EPS and FY2027 earnings at $0.36 EPS.

A number of other research firms have also weighed in on RMTI. Weiss Ratings raised Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 3rd. Wall Street Zen raised shares of Rockwell Medical to a “hold” rating in a report on Saturday, July 25th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $20.00.

Rockwell Medical Stock Performance

Shares of RMTI opened at $7.85 on Monday. The stock’s 50-day simple moving average is $7.20 and its 200 day simple moving average is $7.82. The stock has a market capitalization of $31.64 million, a price-to-earnings ratio of -5.86 and a beta of 1.64. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.00 and a current ratio of 3.25. Rockwell Medical has a 52-week low of $4.89 and a 52-week high of $17.20.

Rockwell Medical (NASDAQ:RMTI) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). Rockwell Medical had a negative return on equity of 14.03% and a negative net margin of 7.33%.The company had revenue of $17.78 million during the quarter, compared to the consensus estimate of $17.82 million.

Hedge Funds Weigh In On Rockwell Medical

A hedge fund recently raised its position in Rockwell Medical stock. Renaissance Technologies LLC raised its stake in Rockwell Medical, Inc. (NASDAQ:RMTI) by 36.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 639,120 shares of the company’s stock after buying an additional 170,800 shares during the period. Renaissance Technologies LLC owned about 1.62% of Rockwell Medical worth $571,000 at the end of the most recent quarter. 23.31% of the stock is owned by institutional investors.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.